UPDATED: Hedge fund aims to oust Depomed board for ‘troubling record’

Eric Palmer If Depomed thought it was free to chart its own course after foiling a takeover by Horizon Pharma last year, it can think again. A hedge fund practiced in the art of board ...

GSK wins European regulator nod for new gene therapy

Ben Adams GlaxoSmithKline has won a key recommendation from the European regulator the EMA today for Strimvelis–a groundbreaking new gene therapy for children living with an incredibly ...

Revved-up Tecfidera sales power Biogen in Q4

Eric Palmer Biogen CEO George Scangos and his team tamped down investor expectations earlier this month at the J.P. Morgan Healthcare Conference, saying that the company faced headwinds. ...

Novartis divvies up troubled Alcon; targets $1B in cuts in R&D and manufacturing rejig

Tracy Staton Novartis has a problem with its eye-care unit Alcon: It's not performing. As expected, the division dragged down the Swiss drugmaker's fourth-quarter and full-year ...

Sanofi and Regeneron likely to cough up royalties to end Amgen’s PCSK9 patent suit: Analyst

Tracy Staton One of the hottest races for market share in pharma these days is between Amgen's cholesterol-fighter Repatha and Praluent, from Sanofi and Regeneron. They're apparently ...

J&J’s new launches deliver, but overall sales fall short on hep C, strong dollar

Carly Helfand Johnson & Johnson's hep C sales have been nosediving, and the fourth quarter provided more of the same on that front. But in the quarter, a strong dollar ...

Merus pulls forward target date for solid tumor data, reiterates intent to file IPO

Nick Paul Taylor Merus has shaved months off the date on which it expects to release data from a Phase I/II trial of its lead bispecific antibody in HER2-expressing solid tumors. The ...

China’s CARsgen raises $30M for CAR-T work

John Carroll Shanghai-based CARsgen Therapeutics has rounded up a $ 30 million B round to advance its work on CAR-T therapies. The biotech has been working on personalized CAR-T programs, ...

Pressure mounts at GSK, with U.S. hedge fund leading calls for exec shakeup

Tracy Staton Another big investor is putting the screws to GlaxoSmith Kline. Och-Ziff Capital Management has built up a sizable stake in the London-based drugmaker, The Sunday Times ...

Pfizer’s Ibrance clears first hurdle to early access in U.K.

Carly Helfand Pfizer's new cancer standout, Ibrance, has taken its first step toward joining the U.K.'s Early Access to Medicines program, winning the "promising innovative ...

GlaxoSmithKline bails on Basilea’s eczema drug, nixing a $72M payout

Damian Garde GlaxoSmithKline has abandoned its plot to win FDA approval for an eczema treatment from Basilea Pharmaceutica, ending a project that could have paid its partner about $ ...

Vasopharm taps investors for €20M to fund PhIII trial of brain injury treatment

Nick Paul Taylor Vasopharm has emerged from talks with investors armed with €20 million ($ 22 million) to hustle its treatment for traumatic brain injury through Phase III. The ...
Page 1 of 5012345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS